^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SAR441000

    i
    Other names: SAR441000, SAR 441000, BNT131
    Associations

    News

    Trials
    Company:
    BioNTech, Sanofi
    Drug class:
    IL-15R agonist, IFNα stimulant, IL-12 stimulant, Cytokine modulator, GM-CSF stimulant
    Related drugs:
    Associations

    News

    Trials
    9ms
    A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=77, Terminated, Sanofi | Completed --> Terminated; Sponsor terminated the study for non-safety reasons
    Trial termination • Combination therapy • Metastases
    |
    Libtayo (cemiplimab-rwlc) • SAR441000
    9ms
    A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=77, Completed, Sanofi | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    Libtayo (cemiplimab-rwlc) • SAR441000
    4years
    [VIRTUAL] A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors (SITC 2020)
    These data support further clinical evaluation of SAR441000. Ethics Approval The study was approved by each participating Institution’s Ethics or Institutional Review Board(s).
    P1 data • Combination therapy
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B)
    |
    Libtayo (cemiplimab-rwlc) • SAR441000
    4years
    [VIRTUAL] A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors (SITC 2020)
    These data support further clinical evaluation of SAR441000. Ethics Approval The study was approved by each participating Institution’s Ethics or Institutional Review Board(s).
    P1 data • Combination therapy
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B)
    |
    Libtayo (cemiplimab-rwlc) • SAR441000